Similar findings have been observed in multiple myeloma, where the combination of Decitabine and HDACi Quisinostat reduced MDSC and induced temporal changes in memory T cells in the bone marrow while reducing MYC expression in tumor cells (11). This evidence concerns the gene MYC and neoplasm.